Date: 2015-03-25
Type of information: Interim results
phase: 1
Announcement: interim results
Company: Alzprotect (France)
Product: AZP2006 - N-(3-(4-(3-(diisobutylamino)propyl)piperazin-1-yl)propyl)-1H-benzo[d]imidazol-2-amine disulphate salt
Action mechanism:
Disease: progressive supranuclear palsy, Alzheimer disease
Therapeutic area: Rare diseases - Neurodegenerative diseases
Country: France
Trial details:
Latest
news: * On March 25, 2015, Alzprotect announced the end of the first clinical trial with its lead product AZP2006 on healthy human patients. The first part of this phase 1 trial investigated the safety and tolerability of escalating doses of AZP2006 on 56 healthy volunteers. No side effects was detected for all the doses,up to 360 mg. The French healthcare agency, ANSM (Agence Nationale de Sécurité du Médicament), has granted the authorization to continue the trial with repeated doses. Eight healthy patients will receive three doses a day over ten days. This trial will end in June 2015. A last study will also involve older patients 50 to 75 years of age.
